Search results
Pfizer reports dip in first quarter profits, yet beats estimates
dpa international via Yahoo Finance· 10 hours agoThe US pharmaceutical giant Pfizer on Wednesday said its earnings for the first quarter had declined...
Pfizer’s first-quarter results top estimates, while drugmaker boosts full-year profit outlook
Market Watch· 15 hours agoAn expected drop in COVID-19-related product sales, including antiviral Paxlovid and vaccine...
Pfizer: Q1 Earnings Snapshot
Midland Reporter-Telegram· 15 hours agoNEW YORK (AP) — NEW YORK (AP) — Pfizer Inc. (PFE) on Wednesday reported first-quarter...
Pfizer Q1 earnings: non-Covid product sales help post revenues of $14.9 billion despite Comirnaty,...
Invezz· 15 hours agoPfizer Inc. has announced its financial outcomes for the first quarter of 2024, displaying strong...
Pfizer Sees Less Revenue From Covid-19 Treatments, Stock Faces Headwinds Ahead Of Q1 Earnings - ...
Benzinga· 1 day agoPfizer's Q1 earnings report expects EPS of 49 cents and $13.09 billion in revenues. Stock has...
Analyst Report: Pfizer Inc.
Morningstar Research via Yahoo Finance· 9 hours agoPfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types ...
Here's How to Play Pfizer (PFE) Stock Ahead of Q1 Earnings
Zacks via Yahoo Finance· 2 days agoPfizer (PFE) expects its operational revenues to improve, driven by its in-line products like...
Pfizer Stock Rises as Outlook Raised After Earnings Beat
Barrons.com· 14 hours agoPfizer reports first-quarter adjusted earnings of 82 cents a share on revenue of $14.88 billion.Read...
Pfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid sales
CNBC· 14 hours agoPfizer on Wednesday reported first-quarter revenue that beat expectations and hiked its full-year...
Pfizer plans to be 'very active' in obesity market, but CEO mum on precise R&D plans
FierceBiotech· 8 hours agoPfizer’s 2024 revival tour is off and running, but the Big Pharma remains mum on one critical...